ATTN: We are committed to keeping our patients informed regarding the recent cybersecurity incident involving McKesson. At this time, we are continuing to monitor the situation closely and are working to obtain the most current information available. We will provide updates as we receive additional information from McKesson and learn more about any potential impact. Thank you for your patience and trust as we navigate this situation together. CLICK HERE for more information.

Virginia Oncology Associates

Virginia Oncology Associates

Clinical Research & Trials

Cancer Center » Clinical Research & Trials » Available Trials » USO 24246
Patient Portal Cancer Resources

Listen to our podcast

RSS Feed

USO 24246

A Phase II Study Investigating Fruquintinib plus FOLFIRI as Second-Line Treatment for Participants with Metastatic Colorectal Cancer (mCRC)

 

Disease Types: Gastrointestinal Cancer Research

Eligibility Requirements:

• Subjects must have confirmed mCRC
• Subjects with genetic aberrations are allowed
• No MSI-H and BRAF V600
• Subjects must have received FOLFOX and BEV-based first
line of therapy
• Subjects that received more than 1 treatment regimen
for mCRC are excluded
• Subjects that have received neo/adjuvant therapy and
were disease free for >6 months before recurrence are
eligible
• Subjects who received neo/adjuvant FOLFOX and
progressed within 6 months are excluded
• ECOG score ≤ 2 

For more information on this trial CLICK HERE .

Available at:

Virginia Oncology Associates